...
首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Guizhi-jia-houpu-xingzi decoction attenuates ovalbumin-induced allergic asthma via regulation of Toll-like receptor signal pathway
【24h】

Guizhi-jia-houpu-xingzi decoction attenuates ovalbumin-induced allergic asthma via regulation of Toll-like receptor signal pathway

机译:桂枝甲后朴兴子汤通过调节Toll样受体信号通路减轻卵白蛋白引起的过敏性哮喘

获取原文
           

摘要

Purpose: To study the effect of Guizhi-jia-houpu-xingzi (GHX) on ovalbumin-induced allergic asthma in rats. Methods: An animal model of allergic asthma (AA) in rats was established by intraperitoneal injection (ip) of ovalbumin (OVA). Thereafter, GHX (375 mg/kg) was administered orally for 7 days. Pulmonary function, inflammatory cells, immunoglobulin E (Ig) E, interleukin-4 (IL)-4 and interferon-γ (IFN)-γ in serum and bronchoalveolar lavage fluids (BALF) were determined. Furthermore, mRNA ex pressions of Toll-like receptors (TLRs) signal pathway was determined using real time polymerase chain reaction PCR (q-RT-PCR). Results: GHX (375 mg/kg) significantly decreased respiratory rate (p 0.01) and Penh value (p 0.05) when compared with AA rats. The inflammatory cells (p 0.01) and levels of IL-4 (p 0.01) and IgE (p 0.01) were significantly decreased by GHX treatment when compared with AA rats; whereas IFN-γ (p 0.05) was significantly increased. Furthermore, GHX significantly decreased the mRNA ex pressions of GATA binding protein (GATA)-3 (p 0.01), TRL-2 (p 0.01), TRL-4 (p 0.01), myeloid differentiation factor 88 (MyD88) (p 0.01), TNF receptor associated factor 6 (TRAF6) (p 0.01) and β-arrestin (p 0.01) in lung tissues, relative to AA rats. However, GHX treatment led to significant up-regulation of mRNA ex pression of T-bet (p 0.01). Conclusion: These results demonstrate that GHX possesses a potential for treating allergic asthma via regulation of Toll-like receptor (TLR) signal pathway. They also provide a scientific basis for the probable use of GHX in clinical treatment of allergic diseases in future.
机译:目的:研究桂枝加侯朴星子(GHX)对卵清蛋白诱发的过敏性哮喘大鼠的作用。方法:通过腹腔注射卵清蛋白(OVA)建立大鼠过敏性哮喘(AA)动物模型。此后,口服GHX(375 mg / kg)7天。测定血清和支气管肺泡灌洗液(BALF)中的肺功能,炎性细胞,免疫球蛋白E(Ig)E,白介素4(IL)-4和干扰素-γ(IFN)-γ。此外,使用实时聚合酶链反应PCR(q-RT-PCR)确定了Toll样受体(TLRs)信号通路的mRNA表达。结果:与AA大鼠相比,GHX(375 mg / kg)显着降低了呼吸频率(p <0.01)和Penh值(p <0.05)。与AA大鼠相比,GHX处理可明显降低炎症细胞(p <0.01)和IL-4(p <0.01)和IgE(p <0.01)。而IFN-γ(p <0.05)显着增加。此外,GHX显着降低了GATA结合蛋白(GATA)-3(p <0.01),TRL-2(p <0.01),TRL-4(p <0.01),髓样分化因子88(MyD88)的mRNA表达(与AA大鼠相比,肺组织中的TNF受体相关因子6(TRAF6)(p <0.01)和β-arrestin(p <0.01)。但是,GHX处理导致T-bet的mRNA表达显着上调(p <0.01)。结论:这些结果表明GHX具有通过调节Toll样受体(TLR)信号通路治疗过敏性哮喘的潜力。它们还为将来可能在临床上使用GHX过敏性疾病提供科学依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号